Life Science Partner recruits pharmaceutical veteran and cardiology specialist as chief medical officer
Life Science Partner announces the recruitment of Ross Tonkens, MD, FACP, to become the chief medical officer of Regado Biosciences. Tonkens joins the company from Quintiles Transnational where he served as senior director, medical and scientific services and global scientific head for cardiovascular therapeutics.
Regado Biosciences is a biopharmaceutical company developing antidote-controlled therapeutics via simultaneous rational design of drug-antidote pairs. Regado is initially focusing on the acute care antithrombotics market, with its lead product – REG1 anticoagulation system – the first specific direct-acting, antidote-controlled anticoagulant.
Tonkens is uniquely qualified to lead clinical and regulatory development due to his broad experience leading global teams in the cardiovascular therapeutic category. Since 2001, Tonkens has managed a global team of cardiovascular, pulmonary and critical care physicians who oversee drug and device trials for Quintiles’ clients. In addition, he managed four cardiologists based in Europe and a global portfolio of trials.
“For Regado, Ross was an exceptional find,” says Life Science Partner, founder and president Tom Callaway, MD. “In addition to his clinical trial experience, his role at Quintiles allowed him to work with many early-stage companies – and develop the strategic skills to determine what’s possible to make great science commercially feasible despite finite resources.”
A cardiologist by training, Tonkens combines experience in academic research with strong business analytical skills and accomplishments in corporate pharmaceutical environments.
Tonkens earned his undergraduate and medical degrees from Yale. He continued his training in Los Angeles, as an intern at Cedars-Sinai and residency in diagnostic radiology and internal medicine at UCLA. He returned to Cedars Sinai for his cardiology fellowship.